FDA: Frequently Asked Questions

The U.S. Food and Drug Administration governs a product universe spanning prescription drugs, biologics, medical devices, food, dietary supplements, cosmetics, tobacco, and veterinary medicines — a regulatory footprint that touches nearly every consumer market in the United States. The questions below address how the FDA's classification systems, review pathways, and enforcement mechanisms actually function, where official references live, and what professionals need to understand before engaging with the agency. Each answer draws on the FDA's own published frameworks and statutory authorities.

How does classification work in practice?

FDA classification determines both the regulatory pathway a product must follow and the post-market obligations that attach to it. For medical devices, Congress established a three-class framework under 21 U.S.C. § 360c: Class I devices (low risk, general controls only), Class II devices (moderate risk, general and special controls, typically requiring 510(k) clearance), and Class III devices (highest risk, requiring Premarket Approval). As of the FDA's published device classification database, more than 1,700 distinct device types are catalogued across these three classes.

Drug classification operates differently. The agency distinguishes between new molecular entities, biologics licensed under a Biologics License Application, generic drugs reviewed under an Abbreviated New Drug Application, and over-the-counter monograph products. Each track carries different data requirements, user fees under the Prescription Drug User Fee Act (PDUFA), and review timelines — standard reviews target 12 months while priority reviews target 6 months (FDA PDUFA Performance Reports).

What is typically involved in the process?

Regulatory submissions to the FDA are structured, multi-stage processes. A drug sponsor pursuing a new drug approval follows this general sequence:

1. Preclinical testing — laboratory and animal studies establishing basic safety and pharmacology.
2. Investigational New Drug (IND) application — filed before human trials begin; the FDA has 30 days to place a clinical hold or allow studies to proceed (21 CFR § 312).
3. Phase I, II, and III clinical trials — progressive human studies evaluating safety, dosing, and efficacy under FDA clinical trials oversight.
4. New Drug Application (NDA) or Biologics License Application (BLA) — the full evidentiary submission to CDER or CBER respectively.
5. FDA review and advisory committee consultation — the agency may convene an external advisory panel for novel or high-risk products.
6. Approval, complete response letter, or denial — followed by labeling negotiations and post-market commitment requirements.

Device pathways follow analogous stages: design controls, testing, and submission (510(k), PMA, or De Novo), then post-market surveillance and mandatory adverse event reporting.

What are the most common misconceptions?

Three persistent misconceptions shape costly errors in FDA engagement:

"FDA approval and FDA clearance are the same." They are not. Approval (used for drugs, biologics, and Class III devices via PMA) requires the sponsor to prove safety and effectiveness. Clearance (used for most Class II devices via 510(k)) requires only demonstration of substantial equivalence to a legally marketed predicate device — a materially lower evidentiary threshold.

"GRAS status means unlimited use." The Generally Recognized as Safe designation for food additives applies only to specific uses and exposure levels documented at the time of the determination. A substance with GRAS status for one application may require a Food Additive Petition for a different application.

"Dietary supplements are FDA-approved before sale." They are not. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), manufacturers bear the burden of ensuring safety; the FDA does not review or approve supplements prior to market entry, as detailed in the FDA dietary supplement regulation framework.

Where can authoritative references be found?

Primary FDA regulatory references are publicly available through official government portals:

• Electronic Code of Federal Regulations (eCFR): ecfr.gov — Title 21 contains all FDA regulations.
• FDA Guidance Documents Database: fda.gov/regulatory-information/search-fda-guidance-documents — over 4,000 guidance documents spanning all product areas.
• Federal Register: federalregister.gov — proposed rules, final rules, and notices.
• FDA Law (FD&C Act): fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act

For historical context on statutory development, the FDA history and milestones page traces the evolution of agency authority from the original Pure Food and Drug Act of 1906 through contemporary legislation including the Food Safety Modernization Act of 2011.

Guidance documents are not legally binding in the same manner as regulations, but they represent the agency's current thinking and are functionally authoritative in practice.

How do requirements vary by jurisdiction or context?

FDA jurisdiction is federal and preempts inconsistent state law in defined areas — notably drug labeling under the FD&C Act. However, states retain authority in domains the FDA does not expressly occupy. Compounding pharmacies, for example, are regulated under a dual federal-state framework: Section 503A compounders are primarily subject to state boards of pharmacy, while Section 503B outsourcing facilities fall under full FDA cGMP oversight.

Internationally, FDA requirements diverge from those of peer agencies. The European Medicines Agency (EMA) uses a centralized marketing authorization procedure; Canada's Health Products and Food Branch maintains distinct data requirements for biologics. For import regulations, products entering U.S. commerce must comply with FDA requirements regardless of whether the originating country's standards are equivalent.

Within the United States, context also matters by product category: a substance regulated as a drug in one formulation may be regulated as a dietary supplement, cosmetic, or food in another, based on intended use claims rather than chemical composition.

What triggers a formal review or action?

FDA enforcement activity is triggered by defined statutory and regulatory thresholds. Common triggers include:

• Warning Letters — issued when inspectional findings, labeling violations, or adverse event patterns indicate significant noncompliance; the FDA enforcement actions framework details the procedural steps.
• Import Alerts — activated when a foreign facility or product line has a documented pattern of violations, resulting in automatic detention at the U.S. border without physical examination.
• Mandatory Recalls (devices) — under 21 U.S.C. § 360h, the FDA can order a device recall when there is a reasonable probability of serious adverse health consequences.
• Consent Decrees — negotiated federal court orders compelling operational changes at facilities demonstrating persistent Good Manufacturing Practice failures.
• Emergency Use Authorization (EUA) — triggered by a declared public health emergency under Section 564 of the FD&C Act, allowing use of unapproved products when no adequate alternatives exist, as seen in the FDA emergency use authorization process.

Adverse event reports submitted through MedWatch, facility inspection findings (Form FDA 483), and post-market surveillance data from mandatory device registries all feed the agency's risk-based prioritization model.

How do qualified professionals approach this?

Regulatory professionals — including regulatory affairs specialists, quality engineers, and legal counsel with FDA practice experience — apply structured frameworks rather than product-by-product improvisation.

Pre-submission meetings (Q-Sub program for devices, Type A/B/C meetings for drugs) allow sponsors to obtain written FDA feedback on study design, data requirements, and classification questions before investing in full development programs. The distinction between Type A meetings (immediate dispute resolution) and Type B meetings (pre-IND, end-of-Phase 2, pre-NDA) reflects the agency's structured engagement hierarchy (FDA Formal Meetings Guidance, MAPP 4512.1).

Professionals engaged with FDA drug approval processes treat FDA guidance documents as de facto standards even when legally non-binding, because deviating from guidance without documented scientific justification reliably draws agency scrutiny during review.

Cross-functional teams — combining clinical, CMC (chemistry, manufacturing, and controls), regulatory, and legal expertise — are standard for NDA, BLA, and PMA submissions because each discipline addresses distinct sections that reviewers evaluate independently.

What should someone know before engaging?

Before initiating any formal FDA engagement, several structural realities shape outcomes:

Product jurisdiction must be determined first. Whether a product is a drug, device, dietary supplement, cosmetic, or combination product determines which FDA center has jurisdiction and which statutory framework applies. Misclassification at the outset creates compounding delays.

User fees are a factor in planning. PDUFA fees for a fiscal year 2024 NDA application reached $4,048,844 for applications requiring clinical data (FDA FY2024 PDUFA Fee Schedule). Device makers pay separate Medical Device User Fee Act (MDUFA) fees, with a standard 510(k) fee set at $21,870 for fiscal year 2024.

The FDA's public database is a strategic resource. The FDA's homepage at /index links to searchable databases for approved drugs (Drugs@FDA), cleared and approved devices (510(k) and PMA databases), and enforcement actions — all of which inform competitive intelligence and predicate selection.

Timelines are statutory in some cases, discretionary in others. PDUFA commitments set review clock targets, but complete response letters reset those clocks. Building schedule buffers for each stage is standard professional practice.

Understanding the FDA's mission and authority — grounded in the FD&C Act's mandate to protect public health while enabling access to safe, effective products — provides the interpretive frame for navigating each of the above realities coherently.